stelara
(2)
Dan Baker
Dan Baker is a physician-scientist turned biotech founder who spent two decades at Johnson & Johnson's Janssen division helping bring immunology blockbusters Remicade, Simponi and Stelara to patients, before launching Brisbane-based Kira Biotech in 2019 as its founding CEO. Kira is developing KB312, a first-in-class antibody designed to selectively retrain the immune system rather than broadly suppress it, aimed at autoimmune diseases such as rheumatoid arthritis, lupus and type 1 diabetes. A rheumatologist who taught at the University of Pennsylvania for 18 years, Baker also advises drug-development organisations and serves as a healthcare venture partner.
Jennifer Bergheiser
Jennifer Bergheiser is the Chief Business Officer of eGenesis, the Cambridge biotech turning gene-edited pig organs into a real answer to the transplant waitlist. She runs corporate strategy and all portfolio and commercial development, drawing on more than two decades across big pharma, venture capital, and consulting. Her resume runs from screening deals at Domain Associates to steering the blockbuster autoimmune drug Stelara at Centocor/Johnson & Johnson. At eGenesis she helps commercialize one of medicine's boldest bets: organs grown in pigs, edited dozens of times over, transplanted into living humans.